Cabaletta Bio, Inc. (CABA) vs Sanara MedTech Inc. (SMTI)
A side-by-side comparison of Cabaletta Bio, Inc. and Sanara MedTech Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CABA
Cabaletta Bio, Inc.
$1.97HealthcareDelayed quote: Oct 6, 2026, 1:20 PM EDT
SMTI
Sanara MedTech Inc.
$34.99HealthcareDelayed quote: Oct 6, 2026, 1:15 PM EDT
Total return — CABA vs SMTI
growth of $100 · dividends reinvested · last 7yCABA -79.2% (-20.1%/yr)SMTI +185.9% (+16.2%/yr)SMTI compounded faster over this window
Log scale — wide-divergence pair
CABA SMTI
CABA vs SMTI: by the numbers
- •SMTI is the larger company ($322M vs $321M market cap).
- •Both run net losses; CABA's is the smaller (0.00% vs -29.15% net margin).
Metrics side by side
Valuation
| Metric | CABA | SMTI |
|---|---|---|
| Forward P/E | N/A | 184.13 |
| P/S ratio | N/A | 2.93 |
| P/B ratio | 1.53 | 40.49 |
| EV / EBITDA | N/A | 27.79 |
| FCF yield | N/A | 1.40% |
Profitability
| Metric | CABA | SMTI |
|---|---|---|
| Gross margin | 0.00% | 91.33% |
| Operating margin | 0.00% | 9.36% |
| Net margin | 0.00% | -29.15% |
| ROE | -86.10% | -403.03% |
| ROIC | -85.56% | 18.15% |
Growth (annualized)
| Metric | CABA | SMTI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 40.06% |
| Total return CAGR (5Y) | -28.71% | 0.35% |
Frequently asked
- How have CABA and SMTI total returns compared?
- Over the past 5 years, CABA delivered -28.71% and SMTI delivered 0.35% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Cabaletta Bio ROESanara MedTech ROECabaletta Bio operating marginSanara MedTech operating marginCabaletta Bio revenue growthSanara MedTech revenue growthCabaletta Bio free cash flowSanara MedTech free cash flow
Cabaletta Bio & Sanara MedTech appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.